Sell Signal on SPRB as Losses Mount
-2.70%final return
"Spruce is up from 30 bucks to 120. I don't know if what you think getting wrecked is, but okay. It's fallen a bit from where you bought it probably, right? I bought it at 30. Did you buy it at 200? Some of you guys seem a little overindexed, a little overinvested. Cut your losses for spruce. Please leave me alone."
The speaker criticizes investors who remain overexposed in SPRB after the stock has risen and then retreated, advising them to cut their losses rather than trying to average down. The tone is direct and implies that holding SPRB may lead to further downside.
Entry:$107.50
Target:N/A
Horizon:Expires Nov 13, 2025
Trade CallBearish
High ConvictionScore: 7.6
Stock Idea •The Shkreli Pill • Oct 30, 2025
Long SPRB on Rare Disease Catalyst
-39.76%current return
"Why long SPRB? Well, this is my wheelhouse. Its a rare disease drug company and they have a rare disease from a drug from Biomearin. Biomearin was kind of like the rare disease kings and, um, yeah, basically, um, the drug works, um, really well and, um, itll get FDA approval and itll sell a lot and thats really it. Its worth like 5x what its trading at."
The speaker recommends a long position in SPRB, citing its rare disease focus and the potential for FDA approval as key catalysts. The claim is that the drug is undervalued, trading at approximately one-fifth of its potential value.
Entry:$131.15
Target:N/A
Horizon:Medium-term 3–12 months
Trade CallBullish
High ConvictionScore: 8.2
Stock Idea •The Shkreli Pill • Oct 23, 2025